Ablynx

Ablynx is a late-stage clinical biopharmaceutical company that utilizes its proprietary Nanobody platform to develop therapeutic indications for a wide range of unmet medical needs. The company believes that Nanobodies are at the forefront of next-generation protein therapeutic technologies. Ablynx has over 45 proprietary and collaborative Nanobody programs, spanning hematology, inflammation, infectious diseases, autoimmune disorders, oncology, and immuno-oncology.